Saturday, 10 October 2026European Markets

HOFSETH BIOCARE Stock Rises 9% So Far On Friday, Outperforms Market

Loading stream...

At 11:43 EST on Friday, shares of HOFSETH BIOCARE (HBC.OL) surged by 9.83% to close at kr3.24 at 11:43 EST - marking an upward movement from their last closing price at kr2.95. Although still 25.32% below their 52-week high of kr3.95, the increase suggests the stock is moving in an optimistic manner similar to Oslo Bors Benchmark Index_GI as a whole.

About Hofseth BioCare ASA

Hofseth BioCare ASA of Alesund, Norway serves as a provider of pet and consumer health ingredients both within Norway and internationally. Products offered include Brilliant and OmeGo salmon oils as well as ProGo Salmon Protein Powder.

Financial Health Concerns

However, despite HBC.OL's stock rally, its financial health remains cause for serious concern. Over the past year it reported negative earnings per share of kr-0.37 and its return on equity is also disconcertingly negative at 126.49% indicating significant shareholder equity losses.

Stock Stability

On a positive note, however, the value of HOFSETH BIOCARE's shares remains well above its 50-day moving average of kr2.87 and slightly above its 200-day moving average of kr2.96, suggesting relative mid- to long-term stability.

Revenue Growth and Profitability

As well, the company has witnessed impressive revenue growth; its year-on-year quarterly revenue growth increased by 45.4% year over year to reach 134.43 million during its twelve trailing months period. Unfortunately, however, EBITDA stands at a negative number at -39.65; thus raising concerns over its profitability.

Conclusion

Overall, HOFSETH BIOCARE's stock performance indicates an upward trajectory with promising revenue growth and worrying profitability metrics that call attention to the need for strategic decision-making in order to enhance shareholder returns and bolster overall financial status.

More news about HOFSETH BIOCARE (HBC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com